Insulet Co. (NASDAQ:PODD) Shares Sold by Stevens Capital Management LP

Stevens Capital Management LP lowered its stake in shares of Insulet Co. (NASDAQ:PODD) by 79.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,494 shares of the medical instruments supplier’s stock after selling 5,890 shares during the period. Stevens Capital Management LP’s holdings in Insulet were worth $324,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust grew its stake in shares of Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 123 shares during the last quarter. Allworth Financial LP increased its position in shares of Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 92 shares during the period. Wolff Wiese Magana LLC lifted its stake in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 134 shares during the period. BluePath Capital Management LLC purchased a new stake in Insulet in the 3rd quarter valued at $31,000. Finally, Lindbrook Capital LLC boosted its stake in Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have commented on PODD. Stifel Nicolaus boosted their target price on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Barclays decreased their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. JPMorgan Chase & Co. increased their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Finally, Piper Sandler lowered their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $243.21.

Insulet Trading Up 1.2 %

Shares of PODD stock traded up $2.02 during trading hours on Friday, hitting $166.19. The company had a trading volume of 636,152 shares, compared to its average volume of 862,355. The stock has a market capitalization of $11.64 billion, a PE ratio of 57.07, a price-to-earnings-growth ratio of 3.01 and a beta of 0.98. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The company’s fifty day moving average is $172.00 and its 200 day moving average is $179.25.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. During the same quarter last year, the business earned $0.55 EPS. The business’s revenue was up 37.9% on a year-over-year basis. Research analysts expect that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.90% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.